KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $5.3 million.

  • Ionis Pharmaceuticals' Capital Expenditures fell 4180.65% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.6 million, marking a year-over-year increase of 19344.55%. This contributed to the annual value of $45.3 million for FY2024, which is 9021.21% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Capital Expenditures is $5.3 million, which was down 4180.65% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Capital Expenditures registered a high of $25.5 million during Q4 2024, and its lowest value of -$819000.0 during Q4 2023.
  • For the 5-year period, Ionis Pharmaceuticals' Capital Expenditures averaged around $6.7 million, with its median value being $4.5 million (2024).
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Capital Expenditures tumbled by 11978.74% in 2023, and later soared by 321318.68% in 2024.
  • Ionis Pharmaceuticals' Capital Expenditures (Quarter) stood at $2.5 million in 2021, then skyrocketed by 65.43% to $4.1 million in 2022, then plummeted by 119.79% to -$819000.0 in 2023, then surged by 3213.19% to $25.5 million in 2024, then crashed by 79.33% to $5.3 million in 2025.
  • Its Capital Expenditures stands at $5.3 million for Q3 2025, versus $12.3 million for Q2 2025 and $12.6 million for Q1 2025.